[1]Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H,et al. Augmented renal clearance in critically Ill patients:asystematic review [J].Clin Pharmacokinet, 2018, 57(9):1107-1121.
[2]周冉,张圣雨,沈爱宗.肾功能亢进在危重症患者中的研究进展[J].中国医院药学杂志, 2019, 39(19):2009-2013.
[3]Udy AA, Waele JD, Lipman J. Augmented renal clearance and therapeutic monitoring of β-lactams[J].Int J Antimicrob Agents, 2015, 45(4):331.
[4]唐莲,严晓薇,彭秋菊,等. 肾功能亢进患者万古霉素血药浓度监测与临床疗效分析[J].中国医院药学杂志, 2018, 38(15):1629-1632.
[5]Sime FB,Udy AA,Roberts JA.Augmented renal clearance in critically ill patients:etiology, definition and implications for beta-lactam dose optimization [J].Curr Opin Pharmacol,2015(24):1-6.
[6]Bakke V, Sporsem H, Von der Lippe E,et al. Vancomycin levels are frequently subtherapeutic in critically ill patients:a prospective observational study [J].Acta Anaesthesiol Scand,2017,61(6):627-635.
[7]叶超,王朝晖,王春江.肾功能亢进及其对抗菌药物的药物代谢动力学/ 药物效应动力学影响[J].中华危重症医学杂志( 电子版), 2019, 12(2):133.
[8]Kawano Y, Morimoto S, Izutani Y,et al. Augmented renal clearance in Japanese intensive care unit patients:a prospective study.[J].J Intensive Care, 2016,3(4):62.
[9]陈玥,刘磊,朱曼,等. 神经外科术后患者肾功能亢进对万古霉素血药浓度及疗效的影响[J].临床药物治疗杂志, 2021,19(1):68-71.
[10]Baptista JP,Silva N,Costa E,et al.Identification of the critically ill patient with augmented renal clearance:make do with what you have! [J].ESICM,2014,40(Suppl 1):S110.
[11]Barletta JF,MangramAJ,ByrneM,et al.Identifying augmented renal clearance in trauma patients:Validation of the augmented renal clearance in trauma intensive care (arctic) scoring system [J].J Trauma Acute Care Surg,2017,82(4):665-671.
[12]CarlierM,DumoulinA,JanssenA,et al.Comparison of different equations to assess glomerular filtration in critically ill patients[J].Intensive Care Med,2015,41(3):427-435.
[13]石璐,钟桥,唐莲,等.肾功能亢进及其对抗菌药物的药物代谢动力学/药物效应动力学影响[J].中华危重症医学杂志( 电子版), 2020, 13(4):295-301.
[14]唐莲,陆灏迪,薛盛敏,等.肾功能亢进患者万古霉素的药代动力学及谷浓度影响因素研究[J].国际医药卫生导报,2018,24(5):621-628.
[15]Cojutti PG, Barbarino C, Monte AD, et al. Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance[J].Eur J ClinPharmacol, 2018, 74(8):1091.
[16]唐莲,石璐,薛宏志,等. 肾功能亢进对替考拉宁高剂量治疗方案下患者血药谷浓度的影响[J].中国药房, 2020, 31(21):2650-2655.
[17]陆灏迪,唐莲,方洁,等. 肾功能亢进患者应用万古霉素致急性肾损伤的用药监护[J].药学实践杂志, 2019,37(3): 274-278.
[18]何翠瑶,吴青,吕凤俊,等. 临床药师参与耐甲氧西林金黄色葡萄球菌骨髓炎伴肾功能亢进患儿的治疗实践[J].儿科药学杂志, 2021,27(1): 45-49.
[19]薛盛敏,唐莲,方洁,等. 临床药师参与肾功能亢进患者万古霉素个体化用药的临床实践[J].药学服务与研究, 2019,19(3): 222-225.
[20]马志超,杜鹏强,孙弋,等. 临床药师参与重症感染合并肾功能亢进和低蛋白血症患者的药学实践[J].新视野, 2020,17(6): 7-12.
[21]张小飞,张莉翎,郭晓红,等. 临床药师对 1 例脓毒症伴肾功能亢进患者抗感染治疗的药学监护[J].中国临床药学杂志, 2021,30(1): 57-60.
[22]钟晗,张在丽,崔敏,等. 肾功能亢进对感染性休克患者万古霉素剂量的影响[J].药学服务与研究, 2018,18(6): 423,433,469.
[23]唐莲,丁琦,赵富丽,等. 肾功能亢进患者抗感染治疗的药学监护[J].医药导报, 2017,36(4): 439-441.
[24]李庆云,何娟,余丽芳,等. 一例重症胰腺炎伴肾功能亢进病人的药学服务[J].药学服务与研究, 2016,16(6): 433-438.
[25]Infectious Diseases Committee of China Medical Education Association.Expert consensus on clinical application of antimicrobial pharmacokinetic/pharmacodynamics theory [J].Chinese Journal of Tuberculosis and Respiratory Disease,2018,41(6):409-446.
[26]Tamatsukuri T, Ohbayashi M, Kohyama N,et al. The exploration of population pharmacokinetic model for meropenem in augmented renal clearance and investigation of optimum setting of dose[J].J Infect Chemother,2018,24(10):834-840.
[27]Akers KS, Niece KL, Chung KK,et al. Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients[J].J Trauma Acute Care Surg, 2014, 77(3 Suppl 2):S163-170.
[28]Carlier M,Carrette S,Roberts JA,et al.Meropenem and piperacillin/tazobactam prescribing in critically ill patients:Does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? [J].Crit Care,2013,17(3):R84. |